Proclara Biosciences is a biotechnology company focused on developing new treatments for protein misfolding diseases and seeking for strategies which can redress the neurodegenerative disease molecules of β-amyloid, tau and α-synuclein. Recently, Proclara Biosciences conducted research using recombinant human proteins and announced the completion of $ 47 million E round of financing. At the same time, the focus product candidate NPT088 of the company for the treatment of Alzheimer's disease enters 1B clinical trials.
The financing in this round is led and invested by private investors and Merieux Developpement. The funds will be used to develop product candidates of Alzheimer's disease, Parkinson's disease and other diseases, to support further clinical studies of NPT088 as well as to promote the study of the latency molecules. So far, Proclara Biosciences has a total financing of $ 101.8 million.
Proclara Biosciences was formerly known as Neuro Phage Pharmaceuticals. CEO Franz Dr. Hefti said the name change is an important milestone, marking that the company will move towards the direction of finding new treatments of weak protein misfolding diseases to address the urgent needs of the majority of patients.
Proclara provides transformational therapy for Alzheimer's disease and other neurodegenerative diseases. The survey found that most studies of the neurodegenerative diseases only aims for one type of misfolded proteins, while Comprehensive amyloid protein interaction motif owned by Proclara can simultaneously monitor multiple misfolded proteins. NPT088 is the key project of Proclara Bioscience Company. It acts on two protein aggregates which affect Alzheimer's disease: amyloid β (Aβ) and tau protein. It is the most suitable method for treating complex diseases. Flarebio offers recombinant proteins such recombinant Cdh10 at competitive prices.
没有评论:
发表评论